ClinicalTrials.Veeva

Menu

Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

University of Illinois logo

University of Illinois

Status and phase

Withdrawn
Phase 2
Phase 1

Conditions

Angioid Streaks

Treatments

Drug: ranibizumab

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01015495
fvf 3763s

Details and patient eligibility

About

The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.

Full description

Choroidal neovascularization is a hallmark of angioid streaks, and presumably VEGF-driven. Ranibizumab has been shown to be effective in CNV secondary to age-related macular degeneration. Therefore, we hypothesize that ranibizumab may be efficacious in the treatment of CNV secondary to angioid streaks

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 18 years
  • Angioid streaks
  • Subfoveal CNV of recent onset with the following characteristics
  • Absence of subfoveal fibrosis
  • Fibrosis less than 25% of the lesion
  • Presence of blood, subretinal fluid, and/or lipid
  • New onset symptoms within 12 weeks
  • Visual acuity 20/40 to 20/800 on an ETDRS chart

Exclusion criteria

  • Prior treatment of subfoveal CNV in the study eye
  • Age-related macular degeneration
  • Uncontrolled glaucoma
  • High myopia (> -10.00 D spherical equivalent)
  • Prior retinal detachment
  • Media opacity preventing adequate view of the retina
  • Planned cataract surgery in the next 3 months
  • Current chemotherapy for cancer
  • Immunocompromised state
  • Pregnancy (positive pregnancy test) or lactation
  • Premenopausal women not using adequate contraception.
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
  • Participation in another simultaneous medical investigation or trial
  • History of any previous treatment for angioid streaks

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

0 participants in 1 patient group

ranibizumab
Experimental group
Treatment:
Drug: ranibizumab

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems